Off Label NCCN denied as non-formulary by Aetna?

Aetna's specific coverage criteria for off label nccn are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied an Off-Label NCCN-Supported Treatment as Non-Formulary — and How to Appeal

Aetna's formulary is the list of drugs the plan has agreed to cover at defined cost-sharing tiers. A non-formulary denial means the specific drug is either absent from the formulary entirely or placed on a tier that requires a prior authorization or exceptions process that was not completed before the claim was submitted. For off-label oncology or specialty drug use, non-formulary status is common — but it does not make the drug uncoverable. Aetna's policies include a formulary exception pathway, and federal law requires that this pathway exist and be accessible.

### Why This Denial Is Appealable

Aetna is required to maintain a formulary exceptions process under ACA regulations. A formulary exception grants access to a non-formulary drug when a formulary alternative is not clinically appropriate for a specific patient. When the drug is supported by the NCCN Compendium for your indication and no formulary alternative is similarly supported, a formulary exception is often granted. If the exception request was denied, that denial is itself appealable under ACA §2719 and ERISA §503, including through independent external review.

### Federal Appeal Framework

• Formulary exception request: File this first if not already done; it is typically faster than a full appeal and may resolve the issue.
• Internal appeal of the exception denial: File within 180 days. Standard decisions within 30–60 days; urgent within 72 hours.
• External review: Available after a final internal denial; file within approximately four months. The IRO's ruling is binding on Aetna.
• Expedited option: If treatment is urgent, request expedited processing at every stage in writing.

### Documentation to Gather

1. Diagnosis and indication documentation — records establishing your specific diagnosis, histology, and stage that define the NCCN-listed indication for this drug. 2. Formulary alternative review — obtain Aetna's current formulary tier listing; have your prescriber document in writing why each listed formulary alternative is clinically inappropriate for your case. 3. NCCN Compendium support — identification of the specific NCCN category and compendium entry supporting off-label use of this drug for your indication. 4. Prescriber medical-necessity and exception letter — a letter from your physician explaining (a) your diagnosis and clinical situation, (b) why formulary alternatives are unsuitable, and (c) why this specific drug is medically necessary based on NCCN support. 5. Prior treatment history — dated records of any previously tried agents and their outcomes, especially if they are the formulary alternatives Aetna would prefer.

### Criteria-Mapping Structure

Review Aetna's formulary exception criteria in its published Evidence of Coverage or Pharmacy Benefits documents:

| Formulary Exception Criterion | Your Documentation | |---|---| | Drug not clinically substitutable by formulary option | [Prescriber letter, dated, with reasoning per alternative] | | Off-label use supported by NCCN | [NCCN category, indication, edition date] | | Medical necessity established | [Chart notes, diagnosis confirmation, clinical severity] |

Submit the formulary exception request and the appeal concurrently if time is a factor in your treatment. Keeping the timeline compressed is clinically important in oncology settings.